Related Experiment Video

Updated: Nov 5, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.9K

Bailing Capsule combined with α-ketoacid tablets for stage 3 chronic kidney disease: Protocol of a double-blinded,

Xiuhong Hu1, Jing Wang, Hongjuan Yang

  • 1The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.

Medicine
|May 20, 2021
PubMed

Insights

This study investigates if Bailing Capsule (BC) combined with compound α-ketoacid tablets (KA) can improve symptoms and kidney function in stage 3 chronic kidney disease (CKD) patients. The trial is a double-blinded, randomized, controlled study over 8 weeks.

Area of Science:

  • Nephrology
  • Pharmacology
  • Clinical Trials

Background:

  • Chronic kidney disease (CKD) is a progressive condition with increased risks after stage 3.
  • Compound α-ketoacid tablets (KA) are used for CKD adjunctive therapy with protein restriction.
  • Bailing Capsule (BC) is a Chinese medicine that may improve renal function and reduce kidney damage.

Purpose of the Study:

  • To evaluate the efficacy and safety of Bailing Capsule (BC) combined with compound α-ketoacid tablets (KA) in treating stage 3 CKD.
  • To assess the impact of the combined therapy on patient-reported symptoms and clinical markers of kidney function.

Main Methods:

  • A double-blinded, randomized, controlled trial with 1:1 allocation to treatment (BC + KA) or control (BC-simulation + KA) groups.
  • An 8-week treatment course monitoring subjective symptoms, Patient Global Assessment (PGA), serum creatinine, cystatin C, and estimated glomerular filtration rate (eGFR).
  • Adverse events, vital signs, and physical examinations were recorded; data analyzed using SPSS 21.0.

Main Results:

  • The study is designed to collect data on symptom changes and kidney function markers.
  • Analysis will focus on improvements in fatigue, anorexia, halitosis, nausea, itching, and edema.
  • Changes in serum creatinine, cystatin C, and eGFR will be compared between groups.

Conclusions:

  • The results will determine if BC combined with KA can alleviate symptoms in stage 3 CKD patients.
  • The study aims to establish the effectiveness of this combination therapy for improving kidney function.
  • This trial will provide evidence on the safety and efficacy of BC and KA for CKD management.
Abstract

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.1K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

625

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
167
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
99
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
109
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
307
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
154
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
45